PORTAGE, Mich., USA, Sept. 20, 2024 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it…
Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase…
New patent expected to expire in 2030 Tosymra® (sumatriptan nasal spray) 10mg is indicated and marketed for the acute treatment…
Infusion related reactions in patients receiving 30-minute BRIUMVI infusions were all mild (Grade 1) and resolved completely Data also demonstrate…
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50…
Following approval by the shareholders and the Israel Companies Registrar, Lifeward has completed is rebranding initiative with a formal name…
A New Era of Mental Health: Meet REDI, the App That Listens for Depression SEOUL, South Korea, Sept. 12, 2024…
MIAMI, FL, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…
A past-president of the American Spinal Injury Association, Dr. Tansey brings Lifeward over 30 years of experience in research and…
FDA-authorized RelieVRx now a covered treatment for Highmark's commercial members experiencing chronic low back pain (CLBP) PITTSBURGH, Sept. 9, 2024…